Low Concentrations of C5a Complement Receptor Antibodies Are Linked to Disease Activity and Relapse in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis

被引:6
|
作者
Klapa, Sebastian [1 ,2 ]
Mueller, Antje [3 ]
Koch, Andreas [2 ]
Kerstein-Staehle, Anja [3 ]
Kaehler, Wataru [2 ]
Heidecke, Harald [4 ]
Schinke, Susanne [3 ]
Huber-Lang, Markus [5 ]
Nitschke, Martin [6 ]
Pitann, Silke [3 ]
Augustin, Solveig [3 ]
Karsten, Christian M. [7 ]
Riemekasten, Gabriela [3 ]
Lamprecht, Peter [3 ]
机构
[1] Univ Lubeck, Dept Rheumatol & Clin Immunol, Lubeck, Germany
[2] Christian Albrecht Univ Kiel, Inst Expt Med, German Naval Med Inst, Kronshagen, Germany
[3] Univ Lubeck, Dept Rheumatol & Clin Immunol, Lubeck, Germany
[4] CellTrend GmbH, Luckenwalde, Germany
[5] Univ Ulm, Dept Orthopaed Trauma Hand Plast & Reconstruct Su, Ulm, Germany
[6] Univ Lubeck, Transplant Ctr, Dept Internal Med 1, Lubeck, Germany
[7] Univ Lubeck, Inst Syst Inflammat Res, Lubeck, Germany
关键词
INDEX;
D O I
10.1002/art.42410
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveTo examine concentrations of circulating antibodies targeting C3a and C5a complement receptors in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) and analyze their association with disease activity. MethodsConcentrations of antibodies against C3a and C5a complement receptors (anti-C3aR and anti-C5aR) and plasma complement fragments C3a and C5a were determined in patients with AAV (n = 110; granulomatosis with polyangiitis [GPA; n = 82] or microscopic polyangiitis [MPA; n = 28]), systemic lupus erythematosus (SLE) patients as disease controls (n = 36), and healthy donors (n = 220). C3aR and C5aR expression by circulating neutrophils, monocytes, and T cells was analyzed using flow cytometry. Clinical data were assessed at time of serum sampling and during follow-up for 60 months. ResultsIn AAV, anti-C3aR and anti-C5aR antibodies were decreased (P = 0.0026 and P <= 0.0001, respectively). In remission, anti-C3aR antibody concentrations rose to values comparable to healthy donors, whereas anti-C5aR antibody concentrations did not. In GPA, anti-C5a and anti-C5aR antibody concentrations inversely correlated with each other (r = -0.6831, P = 0.0127). In newly diagnosed GPA, decreased concentrations of anti-C5aR antibodies but not anti-C3aR antibodies were associated with disease activity (P = 0.0009). Moreover, low anti-C5aR antibodies were associated with relapse in GPA (hazard ratio 3.54, P = 0.0009) and MPA (hazard ratio 4.41, P = 0.0041). The frequency of C5aR-expressing cells within T cell populations was increased in GPA (P = 0.0021 for CD4+ T cells; P = 0.0118 for CD8+ T cells), but not in MPA. ConclusionLow concentrations of anti-C5aR antibodies reflect disease activity and are associated with an increased risk for relapse in AAV.
引用
收藏
页码:760 / 767
页数:8
相关论文
共 36 条
  • [21] LOW SERUM COMPLEMENT C3 LEVEL AS A RISK FACTOR FOR RELAPSE OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS: A RETROSPECTIVE COHORT STUDY
    Sakai, H.
    Yamashita, H.
    Nakajima, S.
    Takahashi, Y.
    Kaneko, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1224 - 1224
  • [22] Serum Levels of BAFF and APRIL in Myeloperoxidase Anti-Neutrophil Cytoplasmic Autoantibody-Associated Renal Vasculitis: Association with Disease Activity
    Nagai, Miho
    Hirayama, Kouichi
    Ebihara, Itaru
    Shimohata, Homare
    Kobayashi, Masaki
    Koyama, Akio
    NEPHRON CLINICAL PRACTICE, 2011, 118 (04): : C339 - C345
  • [23] The Effect on Renal Function of the Complement C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
    Merkel, Peter
    Bekker, Pirow
    Yue, Huibin
    Kelleher, Catherine
    Schall, Thomas
    Jayne, David
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [24] THE EFFECT OF AVACOPAN, A COMPLEMENT C5A RECEPTOR INHIBITOR, ON KIDNEY FUNCTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS WITH RENAL DISEASE
    Jayne, David
    Merkel, Peter
    Bekker, Pirow
    McMahon, Jeffrey
    Schall, Thomas J.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [25] Avacopan, a selective C5a receptor antagonist, for anti-neutrophil cytoplasmic antibody-associated vasculitis
    Harigai, Masayoshi
    Takada, Hideto
    MODERN RHEUMATOLOGY, 2022, 32 (03) : 475 - 483
  • [26] Monocyte Chemoattractant Protein-1 in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis: Biomarker Potential and Association with Polymorphisms in the MCP-1 and the CC Chemokine Receptor-2 Gene
    Jonsson, Nina
    Erlandsson, Evelina
    Gunnarsson, Lena
    Pettersson, Asa
    Ohlsson, Sophie
    MEDIATORS OF INFLAMMATION, 2018, 2018
  • [27] The Effect of Treatment with the Complement C5a Receptor Inhibitor Avacopan on Health-Related Quality of Life in ANCA-Associated Vasculitis
    Strand, Vibeke
    Bekker, Pirow
    Yue, Huibin
    Jayne, David R. W.
    Merkel, Peter
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1990 - 1992
  • [28] SERUM TISSUE INHIBITOR OF METALLOPROTEINASES-1 (TIMP-1) IS ELEVATED WITH DISEASE ACTIVITY IN PATIENTS WITH ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES-ASSOCIATED VASCULITIS
    Itabashi, Mitsuyo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [29] Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
    Grayson, Peter C.
    Carmona-Rivera, Carmelo
    Xu, Lijing
    Lim, Noha
    Gao, Zhong
    Asare, Adam L.
    Specks, Ulrich
    Stone, John H.
    Seo, Philip
    Spiera, Robert F.
    Langford, Carol A.
    Hoffman, Gary S.
    Kallenberg, Cees G. M.
    St Clair, E. William
    Tchao, Nadia K.
    Ytterberg, Steven R.
    Phippard, Deborah J.
    Merkel, Peter A.
    Kaplan, Mariana J.
    Monach, Paul A.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67 (07) : 1922 - 1932
  • [30] Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis
    Kataoka, Hiroshi
    Tomita, Tomoko
    Nakanowatari, Mika
    Kondo, Makoto
    Mukai, Masaya
    MODERN RHEUMATOLOGY CASE REPORTS, 2023, 7 (02) : 444 - 447